医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Chi-Med Initiates a Phase II Combination Study of Fruquintinib with Iressa® (gefitinib) in First-Line Non-Small Cell Lung Cancer
Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that it has initiated a Phase II study of a combination therapy using fruquintinib and Iressa® in the first-line setting for patients with advanced or metastatic non-small cell lung cancer (“NSCLC”) in China. Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors (“VEGFR”). The first drug dose was administered on January 9, 2017.… 続きを読む
2017年01月16日 PM05:47
2017年01月16日
2020年迪拜世界博览会启动 Expo Live:一个造福社会的创新与合作项目
2020年迪拜世博会今日启动了其首次公开推出其1亿美元的Expo Live项目,以资助、推动和促进能够改善民生、保护环境的创意项目。… 続きを読む
2017年01月16日
圣路易斯华盛顿大学将举办老龄化问题大型论坛;在上海举行的论坛将聚集大中华区大学研究合作伙伴,讨论应对前所未有的全球性社会挑战
圣路易斯华盛顿大学(Washington University in St. Louis,简称华盛顿大学)及其在大中华区的合作大学将于1月21日在上海举行大型会议,讨论中国人口老龄化带来的全球性挑战。… 続きを読む
2017年01月16日
Washington University in St. Louis to Host Major Forum on Aging; Gathering in Shanghai Brings Together Greater China University Research Partners to Address Unprecedented Global Social Challenge
Washington University in St. Louis (WUSTL) and its partner universities in Greater China will hold a major conference in Shanghai on January 21 on the worldwide challenges arising from China’s aging population.… 続きを読む
2017年01月14日
Tocagen Expands Toca 5, Phase 2/3 Clinical Trial for Recurrent Brain Cancer, to South Korea
Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced its randomized, controlled Phase 2/3 clinical trial, called Toca 5, is now enrolling patients in South Korea. The trial is ongoing in the United States, Canada and Israel. The study compares a cancer-selective virus, Toca 511 (vocimagene amiretrorepvec), in combination with Toca FC (extended-release 5-fluorocytosine), to standard of care in patients with first or second recurrence of glioblastoma or anaplastic astrocytoma who are undergoing resection.… 続きを読む